Development of a next generation prostate diagnostic test will improve detection, prevent needless biopsies and prostatectomies, and potentially improve morbidity and prognosis. The biomarker is present in urinary sample, enabling a test that is noninvasive, simple to use, and widely accessible.

Utilizing PCADM-1 will not only provide a more sensitive and efficient diagnostic method, it might also provide medical professionals a tool to determine optimal therapeutic intervention.